.jpeg)
2026-04-21 04:14:58
This article specifies home storage requirements for the oral HSP90 inhibitor Pimitespib, covering temperature, humidity and light protection to maintain drug stability and efficacy, supporting long-term medication management.
2026-04-21 02:29:17
Cemiplimab (brand name Libtayo) is a fully human PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the U.S. FDA in September 2018, it was the first breakthrough therapy for metastatic or locally advanced cutaneous squamous cell carcinoma. By blocking PD-1 ligand binding to activate T-cell anti-tumor activity, it is now approved for the treatment of multiple cancers including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
2026-04-20 03:57:16
Mirvetuximab soravtansine (brand name Elahere) is the world's first folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by ImmunoGen, USA. It has received full approval from the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2026-04-15 05:07:26
Mitotane, the sole approved drug for adrenocortical carcinoma (ACC), is reaffirmed as the preferred adjuvant therapy in the latest NCCN Guidelines 2026. This article dissects its mechanisms, dosing protocols, safety considerations, and international pricing trends, offering authoritative guidance for Hong Kong, Macau, and overseas patients.
2026-04-13 06:40:50
Trodelvy is a breakthrough antibody-drug conjugate (ADC) targeting Trop-2, approved for metastatic triple-negative breast cancer (mTNBC), urothelial carcinoma, and other Trop-2 positive solid tumors. Learn about its mechanism, indications, safety, and global accessibility.
2026-04-10 05:05:56
Ibrutinib, a BTK inhibitor, targets mantle cell lymphoma, chronic lymphocytic leukemia, and other blood cancers by blocking the B-cell receptor pathway. Monotherapy or combination regimens improve outcomes, while managing risks such as bleeding and infections.
2026-04-10 04:56:03
Axitinib, a targeted therapy, demonstrates significant efficacy in advanced renal cell carcinoma (RCC). Combining with immunotherapy or as monotherapy, it offers innovative first-line and second-line treatment approaches, effectively prolonging survival and improving quality of life while managing potential side effects.
2026-04-09 05:56:04
Trametinib, an oral selective MEK1/2 inhibitor, in combination with dabrafenib revolutionizes treatment for BRAF-mutant melanoma, NSCLC, and rare cancers, offering targeted efficacy and manageable safety profile.
2026-04-09 05:45:58
Pirtobrutinib, an innovative non-covalent BTK inhibitor, provides a treatment option for patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), featuring a unique mechanism and manageable safety profile.
2026-04-09 05:22:20
This article systematically reviews the basic pharmaceutical properties, anti-tumor mechanism of action, approved indications, standard dosage and administration, pre-infusion preparation, and adverse event management of Sacituzumab Govitecan, providing a professional and comprehensive medication reference for oncology patients and clinical healthcare providers.
2026-04-07 04:45:06
The drug properties and mechanism of action of Fulvestrant (brand name Faslodex), systematically sorts out its indications, standard dosage, dose adjustment rules, adverse reactions and safety precautions for single-agent and combined treatment of breast cancer, providing professional reference for clinical diagnosis and treatment as well as patient medication.
2026-04-03 01:52:29
Adagrasib (brand name Krazati) is a highly selective oral KRAS G12C inhibitor, approved by the U.S. FDA for the treatment of KRAS G12C-mutated locally advanced/metastatic non-small cell lung cancer and colorectal cancer. It features excellent blood-brain barrier penetration and a long half-life, providing a precise anti-tumor option for patients with advanced solid tumors.
